

## Certificate of Analysis

### A-Raf, active

#### (Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-956, 14-956-K, 14-956M

Parent Lot # D14SP002N

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

**Product Description:** N-terminal GST-tagged, recombinant, human A-Raf, amino acids 273-end, containing the mutations Y301D and Y302D, expressed by baculovirus in Sf21 insect cells. Purified using glutathione agarose. Purity 58% by SDS-PAGE and Coomassie blue staining. MW = 65kDa.

**Formulation:** 0.14mg/ml of enzyme in 40mM Tris/HCl pH8.0, 200mM NaCl, 0.08mM EGTA, 0.024% Brij-35, 4mM glutathione, 20% (v/v) glycerol, 0.8mM benzamidine, 0.16mM PMSF, 0.08% 2-mercaptoethanol. Frozen solution.

**Storage and Stability:** On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.


**Specific Activity (Parent lot# D14SP002N):** 749U/mg, where one unit of A-Raf, active activity is defined as 1nmol phosphate incorporated into 0.5mg/ml myelin basic protein per minute at 30°C with a final ATP concentration of 100µM.

**Handling Recommendations:** Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY  
NOT FOR USE IN HUMANS OR ANIMALS**

### Quality Control Testing

**Kinase Assay:** 1.5–11.3ng of this lot of enzyme phosphorylated 0.5mg/ml myelin basic protein in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



**MS Tryptic Fingerprint:** Confirmed identity as A-Raf with the translated sequence listed on page three



## Certificate of Analysis

### Kinase Assay Protocol

#### Stock Solutions:

- 2 x Reaction Buffer:** 50mM Tris/HCl pH7.5, 0.4mM EGTA, 1mM sodium orthovanadate, 1mM sodium  $\beta$ -glycerophosphate, 0.02% Triton X-100, 2% glycerol, and 20mM DTT.
- Myelin Basic Protein:** Use at a final assay concentration of 0.5mg/ml. Prepare a 10mg/ml stock and add 1.25 $\mu$ l of stock per assay point.
- MEK1, unactive (cat# 14-420):** Use at a final assay concentration of 2.5 $\mu$ g/ml. Prepare a 10x stock in 2 x Reaction buffer and use 2.5 $\mu$ l per assay point.
- MAPK2, unactive (cat# 14-198):** Use at a final assay concentration of 4.7 $\mu$ g/ml. Prepare a 10x stock in 2 x Reaction buffer and use 2.5 $\mu$ l per assay point.
- A-Raf, active:** Dilute with 50mM Tris/HCl pH7.5, 0.4mM EGTA, 1mM sodium orthovanadate, 1mM sodium  $\beta$ -glycerophosphate, 0.02% Triton X-100, 2% glycerol, 20mM DTT, 30mM sodium chloride, and 2mg/ml BSA. Use 1.5–11.3ng per assay point.
- $[\gamma\text{-}^{33}\text{P}]\text{ATP}$ :** 2.5 x MgAc/ $[\gamma\text{-}^{33}\text{P}]\text{ATP}$  cocktail: 25mM MgAc and 0.25mM ATP to which is added  $[\gamma\text{-}^{33}\text{P}]\text{ATP}$  (specific activity approximately 500 - 800cpm/pmol as required).

#### Assay Procedure (96 well plate format):

- Add 5 $\mu$ l of 2 x reaction buffer per assay to wells.
- Add 1.25 $\mu$ l of dH<sub>2</sub>O.
- Add 2.5 $\mu$ l of MEK1, unactive.
- Add 2.5 $\mu$ l of MAPK2, unactive
- Add 1.25 $\mu$ l of myelin basic protein.
- Add **2.5 $\mu$ l (1.5–11.3ng) A-Raf, active.**
- Add 10 $\mu$ l of diluted  $[\gamma\text{-}^{33}\text{P}]\text{ATP}$  mixture.
- Incubate for 10 minutes at 30°C.
- Stop the reaction by adding 5 $\mu$ l of 3% phosphoric acid.
- Transfer a 10 $\mu$ l aliquot onto the appropriate area of a **P30 Filtermat**.
- Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
- Wash the filtermat once for 2 minutes with methanol.
- Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
- Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 $\mu$ l of 30% phosphoric acid.

# Certificate of Analysis

## A-Raf Sequence Information

<b>Protein</b>	human A-Raf
<b>Tags</b>	N-terminal GST
<b>Native sequence</b>	K231 of the recombinant protein is equivalent to K273 of human A-Raf
<b>Accession number</b>	GenBank U01337.1 The recombinant protein contains the amino acid substitution Y301D and Y302D with reference to GenBank U01337.1. These mutations provide constitutive activation of the enzyme.

### Recombinant A-Raf amino acid sequence:

```

1  MSPILGYWKI  KGLVQPTRL  LEYLEEKYEE  HLYERDEGDK  WRNKKFELGL  EFPNLPYYID
61  GDVKLTQSM  IIRYIADKHN  MLGGCPKERA  EISMLEGAVL  DIRYGVSRIA  YSKDFETLKV
121  DFLSKLPEML  KMFEDRLCHK  TYLNGDHVTH  PDFMLYDALD  VVLYMDPMCL  DAFPKLVCFK
181  KRIEAIPOID  KYLKSSKYIA  WPLQGWQATF  GGDHPPKSD  LEVLFQGPEF  KSPAQRERK
241  SLADDKVKV  NLGYRDSGDD  WEVPPSEVQL  LKRIGTGSFG  TVFRGRWHGD  VAVKVLKVSQ
301  PTAEQAQAFK  NEMQVLRKTR  HVNILLFMGF  MTRPGFAIIT  QWCEGSSLYH  HLHVADTRFD
361  MVQLIDVARQ  TAQGMDYLHA  KNIIHRDLKS  NNI FLHEGLT  VKIGDFGLAT  VKTRWGAQP
421  LEQPSGSVLW  MAAEVIRMQD  PNPYSFQSDV  YAYGVVLYEL  MTGSLPYSHI  GCRDQIIFMV
481  GRGYLSPDLS  KISSNCPKAM  RRLSDCLKF  QREERPLFPQ  ILATIELLQR  SLPKIERSAS
541  EPSLHRTQAD  ELPACLLSAA  RLVP
  
```

### Recombinant A-Raf nucleotide sequence:

```

1  atgtccccta  tactaggtta  ttggaaaatt  aagggccttg  tgcaaccac  tcgacttctt
61  ttggaatata  ttgaagaaaa  atatgaagag  catttgtatg  agcgcgatga  aggtgataaa
121  tggcgaaaca  aaaagtttga  attgggtttg  gagtttccca  atcttcctta  ttatattgat
181  ggtgatgtta  aattaacaca  gtctatggcc  atcatacgtt  atatagctga  caagcacaac
241  atgttgggtg  gttgtccaaa  agagcgtgca  gagatttcaa  tgcttgaagg  agcggttttg
301  gatattagat  acggtgtttc  gagaattgca  tatagtaaag  actttgaaac  tctcaaagtt
361  gattttctta  gcaagctacc  tgaaaatgctg  aaaatgttcg  aagatcgttt  atgtcataaa
421  acataattaa  atggtgatca  tgtaacccat  cctgacttca  tgttgtatga  cgctcttgat
481  gttgttttat  acatggacc  aatgtgcctg  gatgcttcc  caaaattagt  ttgttttaa
541  aaacgtattg  aagctatccc  acaaattgat  aagtactga  aatccagcaa  gtatatagca
601  tggcctttgc  agggctggca  agccacgttt  ggtggtggcg  accatcctcc  aaaatcggat
661  ctggaagtcc  tgttccaggg  gcccaattc  aagtcaccag  cagagcagcg  cgagcggagg
721  tccttggccg  atgacaagaa  gaaagtgaag  aacctggggt  accgggactc  aggcgatgac
781  tgggaggtag  caccagtgta  ggtgcagctg  ctgaagagga  tcgggacggg  ctggtttggc
841  accgtgtttc  gagggcggtg  gcatggcgat  gtggccgtga  aggtgctcaa  ggtgtcccag
901  cccacagctg  agcaggccca  ggctttcaag  aatgagatgc  aggtgctcag  gaagacgcga
961  catgtcaaca  tcttgctgtt  tatgggcttc  atgaccggc  cgggatttgc  catcatcaca
1021  cagtgggtgtg  agggctccag  cctctaccat  cacctgcatg  tggccgacac  acgcttcgac
1081  atggtccagc  tcatcgacgt  ggcccggcag  actgccagg  gcatggacta  cctccatgcc
1141  aagaacatca  tccaccgaga  tctcaagtct  aacaacatct  tcctacatga  ggggctcacg
1201  gtgaagatcg  gtgactttgg  cttggccaca  gtgaagactc  gatggagcgg  ggcccagccc
1261  ttggagcagc  cctcaggatc  tgtgctgtgg  atggcagctg  aggtgatccg  tatgcaggac
1321  ccgaaccctt  acagcttcca  gtcagacgtc  tatgcctacg  gggttgtgct  ctacgagctt
1381  atgactggct  cactgcctta  cagccacatt  ggctgccgtg  accagattat  ctttatgggtg
1441  ggccgtggct  atctgtcccc  ggacctcagc  aaaatctcca  gcaactgcc  caaggccatg
1501  cggcgctgc  tgtctgactg  cctcaagttc  cagcgggagg  agcggccct  cttccccag
1561  atcctggcca  caattgagct  gctgcaacgg  tcactcccca  agattgagcg  gagtgcctcg
  
```

## Certificate of Analysis

```
1621 gaaccctcct tgcaccgcac ccaggccgat gagttgcctg cctgcctact cagcgcagcc  
1681 cgccttgtgc cttag
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services